US5747469A
(en)
*
|
1991-03-06 |
1998-05-05 |
Board Of Regents, The University Of Texas System |
Methods and compositions comprising DNA damaging agents and p53
|
US6410010B1
(en)
|
1992-10-13 |
2002-06-25 |
Board Of Regents, The University Of Texas System |
Recombinant P53 adenovirus compositions
|
WO1992015680A1
(en)
|
1991-03-06 |
1992-09-17 |
Board Of Regents, The University Of Texas System |
Methods and compositions for the selective inhibition of gene expression
|
FR2717496B1
(fr)
*
|
1994-03-18 |
1996-04-12 |
Rhone Poulenc Rorer Sa |
Virus recombinants, préparation et utilisation en thérapie génique.
|
US6472178B1
(en)
*
|
1998-02-27 |
2002-10-29 |
Regeneron Pharmaceuticals, Inc. |
Nucleic acids encoding a modified ciliary neurotrophic factor and method of making thereof
|
FR2705686B1
(fr)
*
|
1993-05-28 |
1995-08-18 |
Transgene Sa |
Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
|
AU710962B2
(en)
*
|
1993-05-28 |
1999-09-30 |
Transgene S.A. |
Defective adenoviruses and corresponding complementation lines
|
JP3532566B2
(ja)
*
|
1993-06-24 |
2004-05-31 |
エル. グラハム,フランク |
遺伝子治療のためのアデノウイルスベクター
|
US6730507B1
(en)
|
1993-06-24 |
2004-05-04 |
Merck & Co., Inc. |
Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration
|
US6120764A
(en)
*
|
1993-06-24 |
2000-09-19 |
Advec, Inc. |
Adenoviruses for control of gene expression
|
US6080569A
(en)
*
|
1993-06-24 |
2000-06-27 |
Merck & Co., Inc. |
Adenovirus vectors generated from helper viruses and helper-dependent vectors
|
US5919676A
(en)
*
|
1993-06-24 |
1999-07-06 |
Advec, Inc. |
Adenoviral vector system comprising Cre-loxP recombination
|
US7045347B2
(en)
|
1993-06-24 |
2006-05-16 |
Advec, Inc. |
Helper dependent adenovirus vectors based on integrase family site-specific recombinases
|
US6140087A
(en)
*
|
1993-06-24 |
2000-10-31 |
Advec, Inc. |
Adenovirus vectors for gene therapy
|
US20020136708A1
(en)
|
1993-06-24 |
2002-09-26 |
Graham Frank L. |
System for production of helper dependent adenovirus vectors based on use of endonucleases
|
FR2716460B1
(fr)
*
|
1994-02-21 |
2002-08-09 |
Rhone Poulenc Rorer Sa |
Modèle animal de la maladie d'Alzheimer, préparation et utilisations.
|
FR2717495B1
(fr)
*
|
1994-03-18 |
1996-04-12 |
Rhone Poulenc Rorer Sa |
Virus recombinants, préparation et utilisation en thérapie génique.
|
FR2717497B1
(fr)
*
|
1994-03-18 |
1996-04-12 |
Rhone Poulenc Rorer Sa |
Virus recombinants, préparation et utilisation en thérapie génique.
|
FR2717823B1
(fr)
*
|
1994-03-23 |
1996-04-26 |
Rhone Poulenc Rorer Sa |
Virus recombinants, préparation et utilisation en thérapie génique.
|
IL113052A0
(en)
*
|
1994-03-23 |
1995-06-29 |
Rhone Poulenc Rorer Sa |
Recombinant viruses, their preparation and their use in gene therapy
|
FR2726575B1
(fr)
*
|
1994-11-09 |
1996-12-20 |
Rhone Poulenc Rorer Sa |
Virus recombinants, preparation et utilisation en therapie genique
|
FR2717824B1
(fr)
*
|
1994-03-25 |
1996-04-26 |
Rhone Poulenc Rorer Sa |
Virus recombinants, préparation et utilisation en thérapie génique.
|
FR2718150B1
(fr)
*
|
1994-03-29 |
1996-04-26 |
Rhone Poulenc Rorer Sa |
Virus recombinants, préparation et utilisation en thérapie génique.
|
JPH10507061A
(ja)
*
|
1994-04-28 |
1998-07-14 |
ザ ユニバーシティ オブ ミシガン |
アデノウイルス中にパッケージされたプラスミドdnaを用いる遺伝子送達ベクターおよびパッケージング細胞株
|
US6379943B1
(en)
|
1999-03-05 |
2002-04-30 |
Merck & Co., Inc. |
High-efficiency Cre/loxp based system for construction of adenovirus vectors
|
US5851806A
(en)
*
|
1994-06-10 |
1998-12-22 |
Genvec, Inc. |
Complementary adenoviral systems and cell lines
|
CA2192442C
(en)
|
1994-06-10 |
2007-09-25 |
Imre Kovesdi |
Complementary adenoviral vector systems and cell lines
|
GB9506466D0
(en)
*
|
1994-08-26 |
1995-05-17 |
Prolifix Ltd |
Cell cycle regulated repressor and dna element
|
US6465253B1
(en)
|
1994-09-08 |
2002-10-15 |
Genvec, Inc. |
Vectors and methods for gene transfer to cells
|
US5846782A
(en)
|
1995-11-28 |
1998-12-08 |
Genvec, Inc. |
Targeting adenovirus with use of constrained peptide motifs
|
DE69534166T2
(de)
*
|
1994-10-28 |
2006-03-09 |
Trustees Of The University Of Pennsylvania |
Rekombinanter adenovirus und methoden zu dessen verwendung
|
FR2727867B1
(fr)
*
|
1994-12-13 |
1997-01-31 |
Rhone Poulenc Rorer Sa |
Transfert de genes dans les motoneurones medullaires au moyen de vecteurs adenoviraux
|
US5780296A
(en)
*
|
1995-01-17 |
1998-07-14 |
Thomas Jefferson University |
Compositions and methods to promote homologous recombination in eukaryotic cells and organisms
|
US5770442A
(en)
*
|
1995-02-21 |
1998-06-23 |
Cornell Research Foundation, Inc. |
Chimeric adenoviral fiber protein and methods of using same
|
US6127525A
(en)
*
|
1995-02-21 |
2000-10-03 |
Cornell Research Foundation, Inc. |
Chimeric adenoviral coat protein and methods of using same
|
US6974694B2
(en)
|
1995-06-07 |
2005-12-13 |
Advec, Inc. |
Adenoviruses for control of gene expression
|
IL122614A0
(en)
|
1995-06-15 |
1998-08-16 |
Introgene Bv |
Packaging systems for human recombinant adenovirus to be used in gene therapy
|
US6783980B2
(en)
|
1995-06-15 |
2004-08-31 |
Crucell Holland B.V. |
Packaging systems for human recombinant adenovirus to be used in gene therapy
|
WO1997017090A1
(en)
*
|
1995-11-07 |
1997-05-15 |
Baylor College Of Medicine |
Adenovirus-mediated production of bioactive proteins by mammalian cells and animals
|
US6132989A
(en)
*
|
1996-06-03 |
2000-10-17 |
University Of Washington |
Methods and compositions for enhanced stability of non-adenoviral DNA
|
FR2753379B1
(fr)
|
1996-09-13 |
1998-10-30 |
Rhone Poulenc Rorer Sa |
Methode de traitement de la sclerose laterale amyotrophique
|
US6544523B1
(en)
|
1996-11-13 |
2003-04-08 |
Chiron Corporation |
Mutant forms of Fas ligand and uses thereof
|
US6696423B1
(en)
|
1997-08-29 |
2004-02-24 |
Biogen, Inc. |
Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
|
CA2308606A1
(en)
|
1997-11-06 |
1999-05-20 |
Chiron S.P.A. |
Neisserial antigens
|
AU2144999A
(en)
*
|
1998-01-13 |
1999-08-02 |
Claude Gravel |
Viral vectors encoding neurofilament heavy proteins and their use
|
WO1999036559A1
(en)
*
|
1998-01-13 |
1999-07-22 |
Julien Jean Pierre |
Viral vectors expressing self-polymerizing neuronal intermediate filaments and their use
|
AU1956599A
(en)
*
|
1998-01-13 |
1999-08-02 |
Claude Gravel |
Viral vectors encoding neurofilament light proteins and their use
|
DE69941567D1
(de)
|
1998-01-14 |
2009-12-03 |
Novartis Vaccines & Diagnostic |
Antigene aus neisseria meningitidis
|
CN101293920B
(zh)
|
1998-05-01 |
2012-07-18 |
诺华疫苗和诊断公司 |
脑膜炎奈瑟球菌抗原和组合物
|
US20030017138A1
(en)
|
1998-07-08 |
2003-01-23 |
Menzo Havenga |
Chimeric adenoviruses
|
US6929946B1
(en)
|
1998-11-20 |
2005-08-16 |
Crucell Holland B.V. |
Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
|
NZ530640A
(en)
|
1999-04-30 |
2006-06-30 |
Chiron S |
Conserved neisserial antigens
|
US6913922B1
(en)
|
1999-05-18 |
2005-07-05 |
Crucell Holland B.V. |
Serotype of adenovirus and uses thereof
|
US6492169B1
(en)
|
1999-05-18 |
2002-12-10 |
Crucell Holland, B.V. |
Complementing cell lines
|
GB9911683D0
(en)
|
1999-05-19 |
1999-07-21 |
Chiron Spa |
Antigenic peptides
|
GB9916529D0
(en)
|
1999-07-14 |
1999-09-15 |
Chiron Spa |
Antigenic peptides
|
AU784203B2
(en)
|
1999-10-29 |
2006-02-23 |
Glaxosmithkline Biologicals S.A. |
Neisserial antigenic peptides
|
RU2279889C2
(ru)
|
2000-01-17 |
2006-07-20 |
Чирон С.Р.Л. |
ВАКЦИНА ВЕЗИКУЛ НАРУЖНЫХ МЕМБРАН (OMV), СОДЕРЖАЩАЯ БЕЛКИ НАРУЖНОЙ МЕБРАНЫ N.Meningitidis СЕРОЛОГИЧЕСКОЙ ГРУППЫ В
|
AU2001253233B2
(en)
*
|
2000-04-06 |
2006-12-07 |
Kos Pharmaceuticals, Inc. |
Compounds and methods for lowering cholesterol levels without inducing hypertriglyceridemia
|
US20020123093A1
(en)
*
|
2000-04-06 |
2002-09-05 |
Zannis Vassilis I. |
Compounds and methods for lowering cholesterol levels without inducing hypertrigylceridemia
|
DE60138403D1
(de)
|
2000-09-26 |
2009-05-28 |
Crucell Holland Bv |
Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten
|
US7939087B2
(en)
|
2000-10-27 |
2011-05-10 |
Novartis Vaccines And Diagnostics, Inc. |
Nucleic acids and proteins from Streptococcus groups A & B
|
GB0107658D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Streptococcus pneumoniae
|
GB0107661D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Staphylococcus aureus
|
FR2825372B1
(fr)
*
|
2001-06-01 |
2004-06-18 |
Centre Nat Rech Scient |
Pseudotypage des vecteurs vih-1 par des enveloppes de rhabdovirus
|
JP4413617B2
(ja)
|
2001-12-12 |
2010-02-10 |
カイロン ソチエタ ア レスポンサビリタ リミタータ |
Chlamydiatrachomatisに対する免疫化
|
US20030158112A1
(en)
|
2002-02-15 |
2003-08-21 |
Johns Hopkins University School Of Medicine |
Selective induction of apoptosis to treat ocular disease
|
US20050222061A1
(en)
|
2002-04-18 |
2005-10-06 |
Schulte Ralf W |
Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye
|
ES2335657T3
(es)
|
2002-04-25 |
2010-03-31 |
Crucell Holland B.V. |
Medios y metodos para la produccion de vectores de adenovirus.
|
US7148342B2
(en)
|
2002-07-24 |
2006-12-12 |
The Trustees Of The University Of Pennyslvania |
Compositions and methods for sirna inhibition of angiogenesis
|
GB0308198D0
(en)
|
2003-04-09 |
2003-05-14 |
Chiron Srl |
ADP-ribosylating bacterial toxin
|
AU2004262022B2
(en)
*
|
2003-08-01 |
2010-10-28 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Accelerated vaccination
|
US8268324B2
(en)
|
2004-03-29 |
2012-09-18 |
Galpharma Co., Ltd. |
Modified galectin 9 proteins and use thereof
|
US7309606B2
(en)
*
|
2004-09-07 |
2007-12-18 |
The Trustees Of Boston University |
Methods and compositions for treating hypercholesterolemia
|
AR051446A1
(es)
*
|
2004-09-23 |
2007-01-17 |
Bristol Myers Squibb Co |
Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
|
US20070134204A1
(en)
*
|
2005-12-09 |
2007-06-14 |
Henrich Cheng |
Method for treating nerve injury and vector construct for the same
|
US20100015168A1
(en)
|
2006-06-09 |
2010-01-21 |
Novartis Ag |
Immunogenic compositions for streptococcus agalactiae
|
WO2010065834A1
(en)
|
2008-12-04 |
2010-06-10 |
Opko Ophthalmics, Llc |
Compositions and methods for selective inhibition of pro-angiogenic vegf isoforms
|
JP6066035B2
(ja)
|
2009-02-12 |
2017-01-25 |
クルナ・インコーポレーテッド |
グリア細胞由来神経栄養因子(gdnf)関連疾病の、gdnfに対する天然アンチセンス転写物の抑制による治療
|
KR101682735B1
(ko)
|
2009-02-12 |
2016-12-06 |
큐알엔에이, 인크. |
뇌 유래된 신경영양성 인자 (bdnf)에 대한 자연 안티센스 전사체의 저해에 의한 뇌 유래된 신경영양성 인자 (bdnf) 관련된 질환의 치료
|
US20110319317A1
(en)
|
2009-03-04 |
2011-12-29 |
Opko Curna, Llc |
Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirt1
|
CN102482677B
(zh)
|
2009-03-16 |
2017-10-17 |
库尔纳公司 |
通过抑制nrf2的天然反义转录物治疗核因子(红细胞衍生2)‑样2(nrf2)相关疾病
|
JP5904935B2
(ja)
|
2009-03-17 |
2016-04-20 |
クルナ・インコーポレーテッド |
デルタ様1ホモログ(dlk1)に対する天然アンチセンス転写物の抑制によるdlk1関連疾患の治療
|
CA2761152A1
(en)
|
2009-05-06 |
2010-11-11 |
Opko Curna, Llc |
Treatment of lipid transport and metabolism gene related diseases by inhibition of natural antisense transcript to a lipid transport and metabolism gene
|
CA2761142C
(en)
|
2009-05-06 |
2021-06-08 |
Opko Curna, Llc |
Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp
|
KR101749356B1
(ko)
|
2009-05-18 |
2017-07-06 |
큐알엔에이, 인크. |
재편성 인자에 대한 천연 안티센스 전사체의 억제에 의한 재편성 인자 관련된 질환의 치료
|
KR101703695B1
(ko)
|
2009-05-22 |
2017-02-08 |
큐알엔에이, 인크. |
전사 인자 e3(tfe3)에 대한 천연 안티센스 전사체의 억제에 의해 tfe3 및 인슐린 수용체 기질 2(irs2)의 치료
|
EP2435571B1
(en)
|
2009-05-28 |
2016-12-14 |
CuRNA, Inc. |
Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
|
KR101801404B1
(ko)
|
2009-06-16 |
2017-12-20 |
큐알엔에이, 인크. |
콜라겐 유전자에 대한 천연 안티센스 전사체의 억제에 의한 콜라겐 유전자 관련된 질환의 치료
|
KR101702689B1
(ko)
|
2009-06-16 |
2017-02-06 |
큐알엔에이, 인크. |
Pon1에 대한 천연 안티센스 전사체의 억제에 의한 파라옥소나제 1(pon1) 관련된 질환의 치료
|
ES2618894T3
(es)
|
2009-06-24 |
2017-06-22 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con el receptor del factor de necrosis tumoral 2 (tnfr2) por inhibición del transcrito natural antisentido para tnfr2
|
CN102482672B
(zh)
|
2009-06-26 |
2016-11-09 |
库尔纳公司 |
通过抑制唐氏综合征基因的天然反义转录物治疗唐氏综合征基因相关疾病
|
CN102762731B
(zh)
|
2009-08-05 |
2018-06-22 |
库尔纳公司 |
通过抑制针对胰岛素基因(ins)的天然反义转录物来治疗胰岛素基因(ins)相关的疾病
|
EP2470657B1
(en)
|
2009-08-25 |
2019-10-23 |
CuRNA, Inc. |
Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap
|
RU2639550C2
(ru)
|
2009-12-16 |
2017-12-21 |
Курна, Инк. |
Лечение заболеваний, связанных с сайт-1 мембраносвязанной пептидазой транскрипционных факторов (mbtps1), путем ингибирования природного антисмыслового транскрипта к mbtps1
|
EP2515947B1
(en)
|
2009-12-23 |
2021-10-06 |
CuRNA, Inc. |
Treatment of uncoupling protein 2 (ucp2) related diseases by inhibition of natural antisense transcript to ucp2
|
RU2609631C2
(ru)
|
2009-12-23 |
2017-02-02 |
Курна, Инк. |
Лечение заболеваний, связанных с фактором роста гепатоцитов (фрг), посредством ингибирования природного антисмыслового транскрипта к фрг
|
KR101838305B1
(ko)
|
2009-12-29 |
2018-03-13 |
큐알엔에이, 인크. |
NRF1(Nuclear Respiratory Factor 1)에 대한 천연 안티센스 전사체의 억제에 의한 핵 호흡 인자 1 관련된 질환의 치료
|
CN102770540B
(zh)
|
2009-12-29 |
2017-06-23 |
库尔纳公司 |
通过抑制肿瘤蛋白63(p63)的天然反义转录物而治疗p63相关疾病
|
CN102906264B
(zh)
|
2010-01-04 |
2017-08-04 |
库尔纳公司 |
通过抑制干扰素调节因子8(irf8)的天然反义转录物而治疗irf8相关疾病
|
WO2011085066A2
(en)
|
2010-01-06 |
2011-07-14 |
Curna, Inc. |
Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene
|
US9200277B2
(en)
|
2010-01-11 |
2015-12-01 |
Curna, Inc. |
Treatment of sex hormone binding globulin (SHBG) related diseases by inhibition of natural antisense transcript to SHBG
|
ES2671877T3
(es)
|
2010-01-25 |
2018-06-11 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con la RNASA (H1) mediante inhibición del transcrito antisentido natural a RNASA H1
|
KR101838308B1
(ko)
|
2010-02-22 |
2018-03-13 |
큐알엔에이, 인크. |
피롤린-5-카르복실레이트 환원효소 1(pycr1)에 대한 천연 안티센스 전사체의 억제에 의한 pycr1과 관련된 질환의 치료
|
KR101900962B1
(ko)
|
2010-04-09 |
2018-09-20 |
큐알엔에이, 인크. |
섬유아세포 성장 인자 21 (fgf21)에 대한 자연 안티센스 전사체의 저해에 의한 섬유아세포 성장 인자 21 (fgf21) 관련된 질환의 치료
|
US9089588B2
(en)
|
2010-05-03 |
2015-07-28 |
Curna, Inc. |
Treatment of sirtuin (SIRT) related diseases by inhibition of natural antisense transcript to a sirtuin (SIRT)
|
TWI531370B
(zh)
|
2010-05-14 |
2016-05-01 |
可娜公司 |
藉由抑制par4天然反股轉錄本治療par4相關疾病
|
DK2576783T3
(en)
|
2010-05-26 |
2018-03-12 |
Curna Inc |
TREATMENT OF ATONAL HOMOLOGY 1- (ATOH1) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTS AT ATOH1
|
EP2593547B1
(en)
|
2010-07-14 |
2017-11-15 |
CuRNA, Inc. |
Treatment of discs large homolog (dlg) related diseases by inhibition of natural antisense transcript to dlg
|
US8993533B2
(en)
|
2010-10-06 |
2015-03-31 |
Curna, Inc. |
Treatment of sialidase 4 (NEU4) related diseases by inhibition of natural antisense transcript to NEU4
|
CA2815212A1
(en)
|
2010-10-22 |
2012-04-26 |
Curna, Inc. |
Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua
|
RU2611195C2
(ru)
|
2010-10-27 |
2017-02-21 |
Курна, Инк. |
Лечение заболеваний, связанных с интерферон- связанным регулятором развития 1 (ifrd1), путем ингибирования природного антисмыслового транскрипта к ifrd1
|
KR102010598B1
(ko)
|
2010-11-23 |
2019-08-13 |
큐알엔에이, 인크. |
Nanog에 대한 자연 안티센스 전사체의 저해에 의한 nanog 관련된 질환의 치료
|
JP6188686B2
(ja)
|
2011-06-09 |
2017-08-30 |
カッパーアールエヌエー,インコーポレイテッド |
フラタキシン(fxn)への天然アンチセンス転写物の阻害によるfxn関連疾患の治療
|
DK2825648T3
(en)
|
2012-03-15 |
2018-10-15 |
Curna Inc |
TREATMENT OF BRAIN-DERIVATIVE NEUROTROPHIC FACTOR (BDNF) -related DISEASES BY INHIBITATION OF NATURAL ANTISENCE TRANSCRIPTION TO BDNF
|
WO2015171918A2
(en)
|
2014-05-07 |
2015-11-12 |
Louisiana State University And Agricultural And Mechanical College |
Compositions and uses for treatment thereof
|
GB201410693D0
(en)
|
2014-06-16 |
2014-07-30 |
Univ Southampton |
Splicing modulation
|
CN107109411B
(zh)
|
2014-10-03 |
2022-07-01 |
冷泉港实验室 |
核基因输出的定向增加
|
EP3285788A4
(en)
|
2015-04-23 |
2018-12-05 |
University of Massachusetts |
Modulation of aav vector transgene expression
|
IL308174A
(en)
|
2015-10-09 |
2024-01-01 |
Univ Southampton |
Gene expression modulation and dysregulated protein expression scanning
|
JP7049249B2
(ja)
|
2015-12-14 |
2022-04-06 |
コールド スプリング ハーバー ラボラトリー |
中枢神経系疾患の処置のための組成物および方法
|
EP3389671A4
(en)
|
2015-12-14 |
2019-07-17 |
Cold Spring Harbor Laboratory |
ANTISENSE OLIGOMERS FOR THE TREATMENT OF ALAGILLE'S SYNDROME
|
US11096956B2
(en)
|
2015-12-14 |
2021-08-24 |
Stoke Therapeutics, Inc. |
Antisense oligomers and uses thereof
|
EP3390636B1
(en)
|
2015-12-14 |
2021-05-19 |
Cold Spring Harbor Laboratory |
Antisense oligomers for treatment of dravet syndrome
|
WO2017106283A1
(en)
|
2015-12-14 |
2017-06-22 |
Cold Spring Harbor Laboratory |
Compositions and methods for treatment of liver diseases
|
CA3005254A1
(en)
|
2015-12-14 |
2017-06-22 |
Cold Spring Harbor Laboratory |
Compositions and methods for treatment of retinitis pigmentosa 18 and retinitis pigmentosa 13
|
GB2599884B
(en)
|
2017-08-25 |
2022-08-31 |
Stoke Therapeutics Inc |
Antisense oligomers for treatment of conditions and diseases
|
US20210268667A1
(en)
|
2017-10-23 |
2021-09-02 |
Stoke Therapeutics, Inc. |
Antisense oligomers for treatment of non-sense mediated rna decay based conditions and diseases
|
JP2021523227A
(ja)
|
2018-05-04 |
2021-09-02 |
ストーク セラピューティクス,インク. |
コレステリルエステル蓄積症の処置のための方法及び組成物
|
US11845797B2
(en)
|
2018-07-03 |
2023-12-19 |
Marengo Therapeutics, Inc. |
Anti-TCR antibody molecules and uses thereof
|
EP3831949A4
(en)
|
2018-07-30 |
2022-05-04 |
Gene Therapy Research Institution Co., Ltd. |
METHODS OF INCREASING GENE EXPRESSION BY AN AAV VECTOR
|
KR20230022409A
(ko)
|
2020-05-11 |
2023-02-15 |
스톡 테라퓨틱스, 인크. |
병태 및 질환의 치료를 위한 opa1 안티센스 올리고머
|
BR112023020832A2
(pt)
|
2021-04-08 |
2023-12-19 |
Marengo Therapeutics Inc |
Moléculas multifuncionais ligadas a tcr e seus usos
|
WO2022226291A1
(en)
|
2021-04-22 |
2022-10-27 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating cancer
|